8-K: Accelerate Diagnostics Announces Second Quarter 2024 Financial Results and Successful Pre-Clinical Trial

Accelerate Diagnostics reported its second quarter 2024 financial results, highlighted by a successful pre-clinical trial for its WAVE system and a $15 million capital raise.

Summary

• Accelerate Diagnostics announced its financial results for the second quarter of 2024, ending June 30th.
• The company successfully completed a pre-clinical trial for its WAVE system and Gram-Negative Positive Blood Culture assay, demonstrating strong analytical performance with approximately 95% Essential and Categorical Agreements compared to Broth Microdilution.
• They secured contract extensions with approximately 75% of their U.S. Pheno customer base to longer-term contracts.
• The company added five new contracted Pheno instruments in the U.S., ending the quarter with 350 revenue-generating instruments and 74 more in implementation.
• Accelerate Diagnostics raised an additional $15 million from existing noteholders, which is expected to fund the company through 2025.
• Net sales for the quarter were $3.0 million, a slight increase from $2.9 million in the same quarter last year.
• Consumable product revenues increased by 12% compared to the same period last year.
• Gross margin was approximately 23%, down from 27% in the same quarter last year due to lower capital instrument sales.
• Selling, general, and administrative costs decreased to $5.4 million from $7.6 million year-over-year.
• Research and development costs decreased to $3.9 million from $5.8 million year-over-year.
• The net loss for the quarter was $11.6 million, or $0.50 per share.
• The company ended the quarter with $9.7 million in cash and cash equivalents, down from $15.8 million at the start of the quarter.
• Year-to-date net sales were $5.9 million, compared to $5.7 million for the same period last year.
• Year-to-date gross margin was approximately 24%, compared to 23% for the same period last year.
• Year-to-date net loss was $25.8 million, or $1.16 per share.

Sentiment

Score: 5

Explanation: The document presents mixed results. While the pre-clinical trial was successful and the company secured additional funding, the financial results show a decrease in gross margin and a significant net loss. The company is also burning through cash. The sentiment is neutral to slightly negative.

Positives

• The pre-clinical trial for the WAVE system showed strong analytical performance.
• The company secured long-term contracts with a significant portion of its U.S. Pheno customer base.
• Consumable product revenue increased by 12% year-over-year.
• Selling, general, and administrative costs decreased significantly year-over-year.
• Research and development costs decreased significantly year-over-year.
• The company successfully raised $15 million in additional funding.

Negatives

• Gross margin decreased to 23% from 27% due to lower capital instrument sales.
• The company experienced a net loss of $11.6 million for the quarter.
• Cash and cash equivalents decreased from $15.8 million to $9.7 million during the quarter.

Risks

• The company's financial condition and ability to obtain additional capital remain a concern.
• There are risks associated with obtaining regulatory approvals for their products.
• The company faces potential challenges from volatility in the global economy, supply chain constraints, and inflationary pressures.
• There is a risk of less than expected operating and financial benefits from cost cutting measures.

Future Outlook

The company anticipates that the recent $15 million capital raise will fund operations through 2025 and provide runway to further deliver on its Wave strategic milestones. They are also continuing to invest in new product development and are working on commercial partnerships.

Management Comments

• Jack Phillips, President and CEO, stated that the pre-clinical trial was a success.
• Mr. Phillips also mentioned that the $15 million capital raise will fund the company through 2025 and provide runway to further deliver on Wave strategic milestones.

Industry Context

The company operates in the in-vitro diagnostics industry, focusing on solutions for antibiotic resistance and sepsis. The successful pre-clinical trial and the launch of the WAVE system are significant steps in this space. The company's focus on faster results compared to existing methods is a key differentiator.

Comparison to Industry Standards

• Accelerate Diagnostics competes with companies like BioMérieux and Cepheid in the diagnostics space.
• The reported 95% agreement in the pre-clinical trial is a strong result, comparable to or exceeding the performance of similar diagnostic systems.
• The company's focus on reducing time to results is a key competitive advantage, with claims of 1-2 days faster results than existing methods.
• The company's gross margin of 23% is lower than some established players in the industry, which can have gross margins of 50% or higher, indicating a need for improvement in cost management or pricing strategies.
• The company's continued losses and cash burn highlight the challenges of commercializing new diagnostic technologies, which is a common theme in the industry.

Stakeholder Impact

• Shareholders may be concerned about the net loss and decrease in cash reserves.
• Employees may be impacted by the cost-cutting measures and lower employee-related expenses.
• Customers may benefit from the new WAVE system and the company's focus on faster results.
• Suppliers may be affected by the company's financial situation and cost-cutting measures.
• Creditors may be concerned about the company's ability to meet its financial obligations.

Next Steps

• The company will file full financial results for the quarter ended June 30, 2024, on Form 10-Q.
• Management will host a conference call on August 8, 2024, to review the second quarter results.
• The company will continue to work on the commercial launch of the WAVE system.
• The company will continue to pursue strategic alternatives with the assistance of Perella Weinberg Partners.

Key Dates

Keywords

Accelerate Diagnostics, WAVE System, Pheno, Financial Results, Pre-clinical Trial, Gram-Negative Positive Blood Culture, Consumables, Diagnostics, Antibiotic Resistance, Sepsis